Patents by Inventor Michael Rotte

Michael Rotte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF SELECTIVELY TREATING ASTHMA USING IL-13 ANTAGONISTS
    Publication number: 20200178741
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an IL-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-13 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist.
    Type: Application
    Filed: December 10, 2019
    Publication date: June 11, 2020
    Inventors: Michael ROTTE, Steven LEWITZKY, Amy DAMASK
  • Methods Of Selectively Treating Asthma Using IL-13 Antagonists
    Publication number: 20190082912
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an IL-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-13 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist.
    Type: Application
    Filed: July 24, 2018
    Publication date: March 21, 2019
    Inventors: Michael Rotte, Steven Lewitzky, Amy Damask
  • Methods of selectively treating asthma using IL-13 antagonists
    Patent number: 10066267
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an IL-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-13 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: September 4, 2018
    Assignee: Novartis AG
    Inventors: Amy Damask, Steven Lewitzky, Michael Rotte
  • Methods Of Selectively Treating Asthma Using IL-13 Antagonists
    Publication number: 20170029894
    Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an IL-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-13 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist.
    Type: Application
    Filed: April 8, 2015
    Publication date: February 2, 2017
    Inventors: Amy Damask, Steven Lewitzky, Michael Rotte